Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
COPENHAGEN, June 21, 2007-Novo Nordisk today announced clinicalresults from the first of five phase 3 studies with liraglutide -the once-daily human GLP-1 analogue. The 26-week study is part ofthe LEAD(TM) (Liraglutide Effect and Action in Diabetes) programmeand included 581 patients with type 2 diabetes inadequatelycontrolled by two of the most widely used oral antidiabetic drugs:metfor...